A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants with Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies.

Trial Identifier: D9961C00001
Sponsor: AstraZeneca
Collaborator:
Fortrea
Start Date: May 2025
Primary Completion Date: June 2027
Study Completion Date: June 2027
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, ON Hamilton, ON, CA, L8S 4K1
CA, QC Sherbrooke, QC, CA, J1G 2E8
CN Beijing, CN, 100730
CN Shanghai, CN, 200001
CN Wuhan, CN, 430022
DE Erlangen, DE, 91054
DE Köln, DE, 50937
DE Magdeburg, DE, 39120
ES Mérida, ES, 06800
ES Sevilla, ES, 41010
ES Valladolid, ES, 47012
FR Bordeaux, FR, 33000
FR Montpellier, FR, 34295
FR Nancy, FR, 54035
FR Paris, FR, 75013
FR Strasbourg Cedex, FR, 67098
FR Toulouse, FR, 31059
GB Glasgow, GB, G31 2ER
GB London, GB, SE5 9RS
GB London, GB, WC1E 6JF
GB Southampton, GB, SO16 6YD
JP Bunkyo-ku, JP, 113-8655
JP Kita-gun, JP, 761-0793
JP Kitakyushu-shi, JP, 807-8555
JP Kyoto, JP, 606-8501
JP Nagasaki-shi, JP, 852-8501
NL AMSTERDAM, NL, 1105 AZ
US, AL Anniston, AL, US, 36207